116 results about "Human papilloma virus infection" patented technology

The invention relates to a method of screening for precursor lesions which can lead to cervical malignancy, methods of detecting and typing human papilloma virus infections, and reagents of use in these methods.

The present invention relates to the intersection of the fields of immunology and protein engineering, and particularly to antigens and vaccines useful in prevention of infection by human papilloma virus. Provided are recombinant protein antigens, compositions, and methods for the production and use of such antigens and vaccine compositions.

The invention discloses a probe and a primer which have nucleotide sequence complementary with HPV DNA, wherein, the probe is selected from SEQ ID Nos: 1 to 13; the primer is selected from SEQ ID SEQ ID Nos: 14 to 39; the invention also discloses a fluorescence identification kit comprising the probe and the primer and used for indentifying nucleic acid amplification infected by high-risk human papillomavirus, which contains 13 varieties of high-risk human papillomavirus subtypes and can finish extracting and detecting 80 to 100 portions of clinical samples DNA in 3 hours. The invention has the advantages of high sensitivity and specificity and low price, thus being easy to be accepted by patients and easy for popularizing and spreading.

Provided are adenoviral vectors for generating an immune response to antigen. The vectors comprise a transcription unit encoding a secretable polypeptide, the polypeptide comprising a secretory signal sequence upstream of a tumor antigen upstream of CD40 ligand, which is missing all or substantially all of the transmembrane domain rendering CD40L secretable. Also provided are methods of generating an immune response against cells expressing a tumor antigen by administering an effective amount of the invention vector. Further provided are methods of generating an immune response against cancer expressing a tumor antigen in an individual by administering an effective amount of the invention vector. Still further provided are methods of generating immunity to infection by human papilloma virus (HPV) by administering an effective amount of the invention vector which enocodes the E6 or E7 protein of HPV. The immunity generated is long term.

The invention discloses an application of polypeptide in preparing preparations for preventing and treating human papilloma virus infection, and belongs to the field of infectious disease treatment. Apolypeptide preparation for preventing and treating human papilloma virus infection is also provided; and the polypeptide preparation takes the polypeptide with effective dose as active ingredients and is prepared by adding pharmaceutically acceptable subsidiary materials or auxiliary components. The polypeptide can be used for the treatment and prevention of human papilloma virus infection, so that the polypeptide is significant in effect; and the polypeptide has no inhibition effects on the normal flora of female genital tracts, so that the polypeptide is good in safety.

The invention relates to the prevention and treatment field of human papillomavirus infection, in particular to an amino acid modification sequence of recombinant human papillomavirus (HPV) L1 capsid protein, a nucleotide sequence encoding the amino acid modification sequence, and a carrier and a transformant containing the nucleotide sequence; and the invention further relates to application of an HPV L1 protein polymer consisting of the amino acid modification sequence to preparing vaccines, pharmaceutical compositions and diagnostic antigen or diagnostic antibodies. In the invention, an HPV L1 protein wild-type sequence is modified to prevent forming of a disulfide bond in the HPV L1 protein, the modification has no significant effect on the structural stability of the recombinant HPV L1 protein, but significantly improves the efficiency of purification process, and directly reduces the reagent consumption, thus effectively lowering the industrial production cost and having great economical benefit.

A method of treating patients having viral infections including herpes simplex virus 1 and 2 infections and human papillomavirus infections by topically administering Product R, a peptide-nucleic acid preparation, by itself or in a composition comprising Product R and other pharmaceutically acceptable carriers for topical administration, is disclosed.

The invention relates to a compound vaccine composition for preventing and treating human papillomavirus infection, a compound vaccine vaginal spray and uses thereof, and belongs to the field of vaccine preparations with targeted treatment indications. The product of the present invention can prevent cervical cancer and treat HPV infection; it is suitable for married women of any age; it can prevent and treat chronic cervicitis and cervical epithelial dysplasia caused by sexually transmitted HPV infection, including CIN I, II, III Degree, inhibit HPV reproduction, prevent cervical cancer.

The invention discloses a charge modified lactoferrin and carrageenin combination medicine which comprises 0.01 part by weight of lactoferrin, 1.5 parts by weight of carrageenin, 5 parts by weight of carbomer, 50 parts by weight of glycerol and 0.1 part by weight of ethylparaben. The combination medicine is one of a gel, a suppository and a dressing. The combination medicine disclosed by the invention can be used for preventing and treating female human papilloma virus infection as well as preventing and treating female gynecological gram-negative bacterium infection.

A Chinese medicine for treating the human papillomavirus infection and clearing the papillomavirus from human body is prepared from safflower and scouring herb.

The invention is a series of synthetic virus-like particles comprising a heterologous conformational epitope useful in the characterization of human papillomavirus infection, and useful to vaccinate individual for protection against HPV 6 and HPV 11 infections, and assays employing the synthetic virus-like particles.

Compositions that comprise a polymer entrapping an oxidizing agent are disclosed. The disclosed compositions are used in the treatment of skin ailments such as human papilloma virus infections.

The invention provides immunotherapeutic and prophylactic bacteriophage viral-like particle (VLPs) which are useful in the treatment and prevention of human papillomavirus (HPV) infections and related disorders, including cervical cancer and persistent infections associated with HPV. Related compositions (e.g. vaccines), nucleic acid constructs, and therapeutic methods are also provided. VLPs and related compositions of the invention induce high titer antibody responses against HPV L2 and protect against HPV challenge in vivo. VLPs, VLP-containing compositions, and therapeutic methods of the invention induce an immunogenic response against HPV infection, confer immunity against HPV infection, protect against HPV infection, and reduce the likelihood of infection by HPV infection.

The invention provides a kit for fluorescent PCR (Polymerase Chain Reaction) detection of a high-risk HPV (Human Papilloma Virus). The kit comprises a nucleic acid releasing agent and a PCR reaction solution, wherein the nucleic acid releasing agent comprises 0.01-05mmol/L surfactin, 20-300mmol/L potassium chloride, 0.01-2% sodium dodecyl sulfate and 0.05-1% ethanol; the PCR reaction solution comprises high-risk HPV16-type and 18-type primer probe sequences and internal standard primer probe sequences. The invention aims at providing a kit for fluorescent quantitative PCR detection of high-risk Human Papilloma Virus, and the kit has the advantages of fastness in operation, simple method, high detection sensitivity and wide detection range. By virtue of the kit, a common fast fluorescent PCR detection is carried out on DNA nucleic acid fragments of the high-risk human papilloma virus in unknown samples, such as cast-off cells of the surface of a verruca acuminata body, women cervical epithelial cells and genital secretion and the detection results can be applied in the auxiliary diagnosis of the high-risk human papilloma virus infection and the early screening of cervical cancer.

The invention provides an HPV (human papilloma virus) high-risk typing fluorescence PCR (polymerase chain reaction) detection kit which comprises a nucleic acid releaser and two or more PCR reaction solutions, wherein the nucleic acid releaser comprises 0.01-0.5 mmol/L surfactin, 20-300 mmol/L potassium chloride, 0.01-2% of sodium dodecylsulfate and 0.05-1% of ethanol. One of the PCR reaction solutions comprises high-risk HPV 16 type and/or 18 type primer probe sequences, and another PCR reaction solution comprises an internal reference primer probe sequence. The kit provided by can be used for carrying out quick fluorescence PCR typing detection on DNA (deoxyribonucleic acid) nucleic acid segments of high-risk HPV in wart surface shedding cells, female cervix epithelial cells, genital secretion and other unknown samples; and the detection result can be used for auxiliary diagnosis of high-risk HPV infection, early screening of cervical carcinoma, follow-up survey of cervix pathological changes and instruction of vaccine development.

The invention provides a traditional Chinese medicine composition used for treating human papillomavirus infection. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 8-12 parts of rhizoma atractylodis stir-fried with bran, 8-12 parts of white atractylodes rhizome stir-fried with bran, 8-12 parts of golen cypress, 20-40 parts of coix seed, 8-12 parts of paris polyphylla, 8-12 parts of isatis root, 20-40 parts of oldenlandia diffusa and 8-12 parts of rhizoma smilacis glabrae; and the aim of treating human papillomavirus infection is achieved by tonifying spleen, benefiting qi, promoting diuresis, clearing heat and detoxifying. The invention also provides a preparation method and an application of the traditional Chinese medicine composition.

The present invention relates to a fluorescent PCR (polymerase chain reaction) detection method for diagnosing low risk type human papilloma virus (HPV) infection, belonging to the in vitro nucleic acid diagnosis field. The present invention comprises a multiple polymerase chain reaction (PCR) system based on fluorescent PCR technique, includes a forward primer and a reverse primer which aim at a plurality of HPV types, as well as a fluorescent probe, and can simultaneously detect DNA comprising six HPV types at most, namely HPV6, 11, 40, 42, 43 and 44, in one reaction tube under proper PCR conditions. The detection method can conveniently and rapidly diagnoss HPV infection in clinical samples, is high in specificity, and has great clinical value for preventing and controlling condyloma acuminatum in an early stage, blocking infection sources and reducing HPV infection.

Provided herein are genetically modified arenaviruses suitable as vaccines against neoplastic diseases or cancer. The invention also relates to pharmaceutical compositions and methods for the prevention or treatment of certain infections causing neoplastic diseases or cancer, such as infections with oncogenic viruses. Specifically, provided herein are pharmaceutical compositions, vaccines, and methods of preventing or treating diseases and conditions caused by and associated with infections with Human Papillomavirus (HPV), such as cervical cancer, anogenital cancer, head and neck cancer and skin cancers. Also provided herein are immunotherapies for the treatment of a neoplastic disease, such as a neoplastic disease caused by infection with oncogenic viruses.